Data from the phase 3 PhALLCON trial support the FDA accelerated approval of ponatinib plus chemotherapy in adult patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia.
Approval Alert | Ponatinib/Chemotherapy in Ph+ Acute Lymphoblastic Leukemia
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer
2
FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy
3
Zenocutuzumab Earns FDA National Priority Voucher in Cholangiocarcinoma
4
Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer
5